Revolution Medicines (RVMD) Receivables - Other (2019 - 2020)
Revolution Medicines (RVMD) posted Receivables - Other of $6.4 million for Q4 2020, down 31.25% on a QoQ basis from $9.3 million in Q3 2020, and down 26.83% year-over-year from $8.7 million in Q1 2020.
Powered by 
Analysis
Revolution Medicines (RVMD) Receivables - Other (2019 - 2020) Analysis & Trends
Revolution Medicines has reported Receivables - Other for 2 years, with the latest figure at $6.4 million in Q4 2020.
- On a quarterly basis, Receivables - Other fell 26.83% year-over-year to $6.4 million in Q4 2020; TTM through Dec 2020 was $6.4 million, a 26.83% decrease from a year earlier, with the FY2020 full-year figure at $6.4 million, down 26.83% from the prior year.
- Receivables - Other was $6.4 million for Q4 2020 at Revolution Medicines, down from $9.3 million in the prior quarter.
- The five-year high for Receivables - Other was $9.3 million in Q3 2020, with the low at $6.4 million in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn |
| 10 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | 6.39 Mn |
| Sep 30, 2020 | 9.30 Mn |
| Jun 30, 2020 | 7.33 Mn |
| Mar 31, 2020 | 8.45 Mn |
| Dec 31, 2019 | 8.74 Mn |